TITLE

RECEPTOR LOGIC/SANOFI PASTEUR DEVELOP TCR FOR VACCINE TESTS

PUB. DATE
April 2008
SOURCE
Worldwide Biotech;Apr2008, Vol. 20 Issue 4, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that biopharmaceutical company Receptor Logic Ltd. has formed a partnership with sanofi pasteur, the vaccines division of sanofi-aventis Group. The companies will develop T Cell Receptor Mimics (TCRm) for the validation and testing of sanofi pasteur vaccines. It states that Receptor Logic is funded and managed by life sciences venture firm Emergent Technologies Inc. Tony Taylor, senior vice president of Emergent, talks about TCRm.
ACCESSION #
31446985

 

Related Articles

  • Receptor Logic Finds Partner to Develop T-Cell Mimics. Hollingsworth, Catherine // BioWorld Today;2/28/2008, Vol. 19 Issue 40, p4 

    The article reports on the plan of Receptor Logic Ltd. to partner with Sanofi Pasteur Inc. to develop T-Cell Receptor Mimics (TCRm) for vaccine research. Receptor Logic will create custom TCRm in support of Sanofi's vaccine programs under their research and exclusive license agreement. It is...

  • Receptor Logic, Sanofi Pair to Develop T-Cell Mimics.  // Bioworld Week;3/3/2008, Vol. 16 Issue 9, p5 

    The article reports on the move of Receptor Logic Ltd. in partnering Sanofi Pasteur Inc. to develop T-Cell Receptor Mimics (TCRm) for vaccine research. According to the article, Receptor Logic will provide custom TCRm through the help of Sanofi vaccine's programs. It reveals that Receptor Logic...

  • Dealing to needle phobia.  // New Zealand Doctor;5/19/2010, p3 

    The article evaluates the Intanza intradermal influenza vaccine from Sanofi Pasteur.

  • Pharma: Clinic Roundup.  // BioWorld Today;7/26/2012, Vol. 23 Issue 144, p9 

    The article reports that the tetravalent dengue vaccine candidate from Sanofi Pasteur has demonstrated proof of efficacy against dengue and has generated antibody response for all four dengue virus serotypes.

  • Sanofi Pasteur Expands Recall of H1N1 Vaccine. Haniff, Haydia // BioPharm International;Mar2010, Vol. 23 Issue 3, p14 

    The article announces that Sanofi Pasteur Inc. in Lyon, France has added six lots of its influenza A (H1N1) 2009 Monovalent Vaccine in prefilled syringes after a test result that shows a decline in its antigen content.

  • Certain vaccines remain in short supply.  // Infectious Diseases in Children;Jul2013, Vol. 26 Issue 7, p18 

    The article reports on the increased demand for the diphtheria-tetanus toxoids-acellular pertussis, inactivated poliovirus (DTaP-IPV)-hepatitis B vaccine manufactured by GlaxoSmithKline due to a shortage of the combined ATaP-IPV-Haemophilus influenzae b conjugate and Daptacel vaccines...

  • Vaccine 'Shan5' launched.  // BioSpectrum;Dec2014, Vol. 12 Issue 12, p16 

    The article discusses the release of the Shan5 pediatric pentavalent vaccine from Sanofi Pasteur Inc.

  • Dengvaxia First Anti-Dengue Vaccine Brings Hope.  // eHEALTH;12/11/2015, p1 

    The article reports on the first anti-dengue vaccine called Dengvaxia developed by the firm Sanofi Pasteur Inc.

  • New polio vaccine available in India.  // Mother & Baby;Jan2016, Vol. 8 Issue 9, p20 

    The article previews the ShanIPV injectable polio vaccine from pharmaceutical firm Sanofi Pasteur.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics